32P Can circulating immune checkpoints and KIT exon 11 mutations be prognostic factors in metastatic gastrointestinal stromal tumors?

Brando, Chiara; Fanale, Daniele; Incorvaia, Lorena; Algeri, Laura; Barraco, Nadia; Corsini, Lidia Rita; Cucinella, A.; Dimino, Alessandra; Filorizzo, Clarissa; Fiorino, Alessia; Madonia, G; Magrin, Luigi; Pedone, Erika; Ricciardi, M; Sciacchitano, Roberta; Scalia, R.; Badalamenti, Giuseppe; Bazan, Viviana; Russo, Anna

doi:10.1016/j.annonc.2021.10.048

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression of PD1 in intratumoral T cells is higher than that in circulating T cells [ 35 ] and its expression shows no correlation with RFS or OS [ 109 ]. Same as sPD-L1, the high expression of soluble PD1 (sPD1) in plasma is associated with PFS and poor prognosis [ 156 – 158 ].…”

Section: Immune Checkpoint Mhc and Other Immune Related Genesmentioning

confidence: 99%

See 1 more Smart Citation

Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers

Chen

Yang

et al. 2023

Mol Cancer

View full text Add to dashboard Cite

Mesenchymal gastrointestinal cancers are represented by the gastrointestinal stromal tumors (GISTs) which occur throughout the whole gastrointestinal tract, and affect human health and economy globally. Curative surgical resections and tyrosine kinase inhibitors (TKIs) are the main managements for localized GISTs and recurrent/metastatic GISTs, respectively. Despite multi-lines of TKIs treatments prolonged the survival time of recurrent/metastatic GISTs by delaying the relapse and metastasis of the tumor, drug resistance developed quickly and inevitably, and became the huge obstacle for stopping disease progression. Immunotherapy, which is typically represented by immune checkpoint inhibitors (ICIs), has achieved great success in several solid tumors by reactivating the host immune system, and been proposed as an alternative choice for GIST treatment. Substantial efforts have been devoted to the research of immunology and immunotherapy for GIST, and great achievements have been made. Generally, the intratumoral immune cell level and the immune-related gene expressions are influenced by metastasis status, anatomical locations, driver gene mutations of the tumor, and modulated by imatinib therapy. Systemic inflammatory biomarkers are regarded as prognostic indicators of GIST and closely associated with its clinicopathological features. The efficacy of immunotherapy strategies for GIST has been widely explored in pre-clinical cell and mouse models and clinical experiments in human, and some patients did benefit from ICIs. This review comprehensively summarizes the up-to-date advancements of immunology, immunotherapy and research models for GIST, and provides new insights and perspectives for future studies.

show abstract

Section: Immune Checkpoint Mhc and Other Immune Related Genesmentioning

confidence: 99%

“…Besides, the expression level of PD-L1 on immune cells is related to worse DFS [154,155]. In plasma, high expression of soluble PD-L1 (sPD-L1) is associated with PFS and poor prognosis [156][157][158][159].…”

Section: Pd1/pd-l1mentioning

confidence: 99%

Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers

Chen

Yang

et al. 2023

Mol Cancer

View full text Add to dashboard Cite

show abstract

32P Can circulating immune checkpoints and KIT exon 11 mutations be prognostic factors in metastatic gastrointestinal stromal tumors?

Cited by 1 publication

References 0 publications

Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers

Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers

Contact Info

Product

Resources

About